These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30637598)

  • 1. Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance.
    Arlett P
    Drug Saf; 2019 May; 42(5):581-582. PubMed ID: 30637598
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance.
    Harinstein L; Kalra D; Kortepeter CM; Muñoz MA; Wu E; Dal Pan GJ
    Drug Saf; 2019 May; 42(5):649-655. PubMed ID: 30569267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global harmonization is not all that global: divergent approaches in drug safety.
    Castle GH; Kelly B
    Food Drug Law J; 2008; 63(3):601-22. PubMed ID: 19031662
    [No Abstract]   [Full Text] [Related]  

  • 4. The drug safety system conundrum.
    Tiedt TN
    Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 6. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 7. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

  • 8. The quantification of drug risks in practice.
    Lee D; Bergman U
    WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852
    [No Abstract]   [Full Text] [Related]  

  • 9. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 10. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA post-marketing safety decisions.
    Klein DF
    J Clin Psychiatry; 2006 Aug; 67(8):1305-6. PubMed ID: 16965212
    [No Abstract]   [Full Text] [Related]  

  • 14. Mandatory pharmacovigilance.
    Maksymowych WP
    CMAJ; 2003 Mar; 168(6):672; discussion 672-3. PubMed ID: 12642413
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter to the ISPE commentary editor.
    Rawson NS
    Pharmacoepidemiol Drug Saf; 2003; 12(1):71-2. PubMed ID: 12616851
    [No Abstract]   [Full Text] [Related]  

  • 16. Surveillance of adverse effects following vaccination and safety of immunization programs.
    Waldman EA; Luhm KR; Monteiro SA; Freitas FR
    Rev Saude Publica; 2011 Feb; 45(1):173-84. PubMed ID: 21181055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New horizons in post-marketing surveillance.
    Waller P; Wood S
    Health Trends; 1993; 25(3):83. PubMed ID: 10131867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA's monitoring of postmarketing studies probed.
    Young D
    Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring and assessing vaccine safety: a European perspective.
    Lopalco PL; Johansen K; Ciancio B; De Carvalho Gomes H; Kramarz P; Giesecke J
    Expert Rev Vaccines; 2010 Apr; 9(4):371-80. PubMed ID: 20370548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.